Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

49
MDXG / MiMedx Group, Inc. 8-K/A (Current Report)

2018-07-11 sec.gov
8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MDXG

31
Avon Products, Nevro Plunge into Tuesday’s 52-Week Low Club

2018-07-10 247wallst
July 10, 2018: Here are four stocks trading with heavy volume among 31 equities making new 52-week lows in Tuesday’s session. On the NYSE advancers and decliners were dead even and on the Nasdaq, decliners led advancers by about 1.4 to 1.
RGLS NVRO MDXG AVP

130
MetLife, MiMedx Group Fall into Friday’s 52-Week Low Club

2018-07-06 247wallst
July 6, 2018: Here are four stocks trading with heavy volume among 32 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 2.7 to 1 and on the Nasdaq, advancers led decliners by about 2.35 to 1.
RGLS MNGA MET MET.PRE MDXG MET MET.PRA

27
MiMedx: A $400 Million Shell Trading Vehicle

2018-07-05 seekingalpha
Based on the strong convictions of the "cabal", extensive financial restatements to come and management changes, one needs to look at MDXG as nothing more than an expensive trading vehicle.
MDXG LHHMQ

61
American Airlines, MiMedx Tumble into Tuesday’s 52-Week Low Club

2018-07-03 247wallst
July 3, 2018: Here are four stocks trading with heavy volume among 43 equities making new 52-week lows in Tuesday’s shortened session. On the NYSE advancers led decliners by about 1.69 to 1 and on the Nasdaq, advancers led decliners by about 1.2 to 1.
CYH MDXG CUKPF AAL CCL CCL CYHHZ CUK

7
Wall Street turns up as US manufacturing index rises in June

2018-07-02 nbr.co.nz
Wall Street turned up in the final hour of trading as the Mexican election brought a new element into trade tensions and manufacturing data showed the economy was still humming.
MDXG

58
Ambev, Ceasars Drop into Monday’s 52-Week Low Club

2018-07-02 247wallst
July 2, 2018: Here are four stocks trading with heavy volume among 142 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 1.16 to 1 and on the Nasdaq, advancers led decliners by about 1.43 to 1.
MDXG CUKPF CZR CCL CCL CUK ABEV

32
The bad news keeps coming for MiMedx and its new auditor EY - MarketWatch

2018-07-02 marketwatch
EY became MiMedx auditor last August but hasn’t yet issued an opinion as the biotech continues losing executives and withdraws more than five years of financial info
LHHMQ MDXG

7
MiMedx CEO and COO resign as investigation of accounting continues - MarketWatch

2018-07-02 marketwatch
MiMedx Group Inc. MDXG, +0.16% on Monday announced its latest executive departures as it continues an investigation of its own accounting that has already concluded it needs to restate all earnings going back to 2012. The company, which makes therapeutic biologics, said Chief Executive and Chairman Parker "Pete" Petit has resigned from his roles, but will remain a board director for now. Chief Operating Officer William "Bill" Taylor has also resigned and is leaving the board.
MDXG

27
MDXG / MiMedx Group, Inc. FORM 8-K (Current Report)

2018-07-02 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MDXG

28
MDXG / MiMedx Group, Inc. FORM 8-K/A (Current Report)

2018-06-25 sec.gov
Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MDXG

71
MDXG / MiMedx Group, Inc. 8-K (Current Report)

2018-06-20 sec.gov
Document UNITED STATES
MDXG

27
Harmony Gold, MiMedx Slink into Thursday’s 52-Week Low Club

2018-06-14 247wallst
June 14, 2018: Here are four stocks trading with heavy volume among 55 equities making new 52-week lows in Thursday’s session. On the NYSE advancers led decliners by about 1.31 to 1 and on the Nasdaq, advancers led decliners by about 1.32 to 1.
HMY MDXG BERY PKD HGMCF

33
MDXG / MiMedx Group, Inc. 8-K/A (Current Report)

2018-06-12 sec.gov
Document UNITED STATES
MDXG

11
MiMedx: Internal Investigation Nears Its End

2018-06-08 seekingalpha
There are no signs of channel stuffing, extensive fraud, or any inappropriate behavior from the company's CEO.
MDXG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 602496101